Commercial Strategies
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Exec Chat: J&J’s Menziuso Looks To Extend Vision Care To Underserved Places And People
Johnson & Johnson Vision recently named Peter Menziuso as company group chairman. In a Q&A with Medtech Insight, he his vision for the company and how the company is in a strong position bring vision care to more people.

Boston Scientific Plans New Facility In Georgia
The company will invest $62.5m for a new manufacturing and supply chain facility in Johns Creek, GA – about 30 miles northeast of Atlanta in Fulton County, according to Georgia Governor Brian Kemp.

Digital Operating Theater Company Proximie Garners $80m in SoftBank-Jobs Raise
To further expand its digital surgical platform, Proximie has completed a series C funding round, gathering a formidable roster of investors.

Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story
Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.

JPM 2022: Dexcom, Edwards, J&J, Medtronic, ResMed
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the first day of the meeting.

Podcast: COVID-19 Continues To Shape MTI 100 Entering 2022
In this special podcast, Medtech Insight commercial/R&D editor Reed Miller talks to In Vivo executive editor Ashley Yeo about the annual MTI 100 list and the major trends facing the top medtech companies entering the third year of the pandemic.

MTI 2022 Outlook: The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the leading global medtechs share their perspectives on the present and the future, from company and health care system standpoints.

Effective Drug Promotion After COVID: Follow Your Audience
Pharmaceutical marketing and sales shifted toward digital by necessity as the COVID-19 pandemic set in, but advertising experts say offline channels still have an important place in an effective, multi-channel promotional strategy. Defining a brand’s key audience and customer drivers should be the determining factor in channel selection, not chasing the next new media platform.

Drug Price Reform Concerns Novartis Pharma President
"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke about competitive rebating and new growth opportunities for anchor brands.

The Case For Covaxin: Ocugen CEO Shankar Musunuri
A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries.

Royal Philips’ IGT Goes For The Structural Heart
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.

Using Data To Improve Rare Disease Diagnosis And Treatment
A deeper understanding of rare diseases – how they differ across geographies and ethnicities, or which genes and biomarkers are most useful targets for new treatments – can help to accelerate and de-risk clinical trials. On the commercial front, patient data and insights could mean the difference between a category leader and a failure.

Royal Philips’ IGT Goes For The Structural Heart
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.

New PBM Models Aim To Lower Out-Of-Pocket Costs
Start-up pharmacy benefit managers such as Capital Rx and Evio hope to shake up the traditional PBM service model with increased drug price transparency, aggregated real-world data and outcomes-based contracting. The big three PBMs which dominate the market represent a formidable challenge.

Using Social Media To Engage Patients And Serve Clients
HashtagHealth builds social media campaigns informed by sophisticated social listening, a focus on specific patient needs and a measurable return on investment for clients. 2021 Rising Leader Brittany Latson, a HashtagHealth co-founder, has leveraged her unique career experiences – at Disney, CVS, and advertising agencies large and small – to create a business that reflects her own values and priorities.

Outpatient Care, Self-Insured Employers Drive Growth Of Non-Opioid Pain Meds
Opioids are cheap, but the economics of clinical practice, including the shift of care from inside the hospital to outpatient or ambulatory facilities, are creating new opportunities for Pacira BioSciences’ non-opioid treatments for pain. Improved reimbursement and increased usage among anesthesiologists are the biggest revenue drivers for the company’s two marketed products.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.